Correlation between mass of muscle and effect of lenvatinib in patients with hepatocellular carcinoma

Correlation between mass of muscle and effect of lenvatinib in patients with hepatocellular carcinoma - Correlation between mass of muscle and effect of lenvatinib

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037380

Enrollment

150

Registered

2019-07-15

Start date

2019-05-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with unresectable HCC and the following features: i) The presence of distant metastases; ii) refractory response to previous transcatheter arterial therapies for HCC; iii) unsuitability for transcatheter arterial therapies due to anatomical reasons; iv) vascular invasion such as tumor thrombus in the portal vein.

Exclusion criteria

Exclusion criteria: i) child-pugh class C, ii) poorly controlled ascites, iii) severe renal dysfunction iv) malignancy except hepatocellular carcinoma

Design outcomes

Primary

Measure	Time frame
The influences of SMI on the occurrence of drug withdral due to severe adverse events (AEs).	—

Secondary

Measure	Time frame
We also investigated the influences of SMI on TTF (Time to treatment failure) and Overall survival(OS).	—

Countries

Japan

Contacts

Public ContactHaruki Uojima

Kitasato University school of medicine Department of gastroenterology

kiruha@kitasato-u.ac.jp042-778-8111

Outcome results